Abstract
The nicotinic acetylcholine receptors (nAChRs) belong to a superfamily of ligand-gated ion channels. Neuronal nAChRs are involved in a variety of complex cognitive processes (learning and memory) and therefore in CNS disorders. These include, for example, Alzheimer’s and Parkinson’s disease, attention deficit hyperactivity disorder, Tourette’s syndrome, schizophrenia, depression, pain and tobacco dependence. Thus, nAChRs present a rational target for the treatment of these pathological processes. Over the past years an increasing number of ligands, especially for the α4β2 subtype has been synthesised. Recent developments reveal increased interest in α7 ligands for the treatment of CNS diseases as well as for pain and inflammation. Unfortunately, only a few companies provide biological data in detail, especially regarding subtype selectivity and functionality. This review provides an overview of the recent patent literature focusing mainly on small molecule ligands.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
